Abstract

Alanine-serine-cysteine transporter 2 (ASCT2, SLC1A5) is the primary transporter of glutamine in cancer cells and regulates the mTORC1 signaling pathway. The SLC1A5 function involves finely tuned orchestration of two domain movements that include the substrate-binding transport domain and the scaffold domain. Here, we present cryo-EM structures of human SLC1A5 and its complex with the substrate, L-glutamine in an outward-facing conformation. These structures reveal insights into the conformation of the critical ECL2a loop which connects the two domains, thus allowing rigid body movement of the transport domain throughout the transport cycle. Furthermore, the structures provide new insights into substrate recognition, which involves conformational changes in the HP2 loop. A putative cholesterol binding site was observed near the domain interface in the outward-facing state. Comparison with the previously determined inward-facing structure of SCL1A5 provides a basis for a more integrated understanding of substrate recognition and transport mechanism in the SLC1 family.

Data availability

All the cryo-EM data were deposited to the Protein Data Bank (PDB ID: 6MP6, 6MPB) and the EMDB (EMD-9187, EMD-9188) for immediate release upon publication.

The following data sets were generated

Article and author information

Author details

  1. Xiaodi Yu

    Medicine Design, Pfizer Inc, Groton, United States
    Competing interests
    Xiaodi Yu, is affiliated with Pfizer Inc. The author has no other competing interests to declare..
  2. Olga Plotnikova

    Medicine Design, Pfizer Inc, Groton, United States
    Competing interests
    Olga Plotnikova, is affiliated with Pfizer Inc. The author has no other competing interests to declare..
  3. Paul D Bonin

    Medicine Design, Pfizer Inc, Groton, United States
    Competing interests
    Paul D Bonin, is affiliated with Pfizer Inc. The author has no other competing interests to declare..
  4. Timothy A Subashi

    Medicine Design, Pfizer Inc, Groton, United States
    Competing interests
    Timothy A Subashi, is affiliated with Pfizer Inc. The author has no other competing interests to declare..
  5. Thomas J McLellan

    Medicine Design, Pfizer Inc, Groton, United States
    Competing interests
    Thomas J McLellan, is affiliated with Pfizer Inc. The author has no other competing interests to declare..
  6. Darren Dumlao

    Medicine Design, Pfizer Inc, Groton, United States
    Competing interests
    Darren Dumlao, is affiliated with Pfizer Inc. The author has no other competing interests to declare..
  7. Ye Che

    Medicine Design, Pfizer Inc, Groton, United States
    Competing interests
    Ye Che, is affiliated with Pfizer Inc. The author has no other competing interests to declare..
  8. Yin Yao Dong

    Structural Genomics Consortium, University of Oxford, Oxford, United Kingdom
    Competing interests
    No competing interests declared.
  9. Elisabeth P Carpenter

    Structural Genomics Consortium, University of Oxford, Oxford, United Kingdom
    Competing interests
    No competing interests declared.
  10. Graham M West

    Medicine Design, Pfizer Inc, Groton, United States
    Competing interests
    Graham M West, is affiliated with Pfizer Inc. The author has no other competing interests to declare..
  11. Xiayang Qiu

    Medicine Design, Pfizer Inc, Groton, United States
    Competing interests
    Xiayang Qiu, is affiliated with Pfizer Inc. The author has no other competing interests to declare..
  12. Jeffrey S Culp

    Medicine Design, Pfizer Inc, Groton, United States
    Competing interests
    Jeffrey S Culp, is affiliated with Pfizer Inc. The author has no other competing interests to declare..
  13. Seungil Han

    Medicine Design, Pfizer Inc, Groton, United States
    For correspondence
    seungil.han@pfizer.com
    Competing interests
    Seungil Han, is affiliated with Pfizer Inc. The author has no other competing interests to declare..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1070-3880

Funding

Y.D. and E.P.C. are members of the SGC, (Charity ref: 1097737) funded by AbbVie, Bayer Pharma AG, Boehringer Ingelheim, the Canada Foundation for Innovation, Genome Canada, GlaxoSmithKline, Janssen, Lilly Canada, Merck & Co., Novartis, the Ontario Ministry of Economic Development and Innovation, Pfizer, São Paulo Research Foundation-FAPESP and Takeda, as well as the Innovative Medicines Initiative Joint Undertaking ULTRA-DD grant 115766 and the Wellcome Trust106169/Z/14/Z.

Reviewing Editor

  1. Lucy Forrest, National Institute of Neurological Disorders and Stroke, United States

Version history

  1. Received: May 1, 2019
  2. Accepted: October 2, 2019
  3. Accepted Manuscript published: October 3, 2019 (version 1)
  4. Version of Record published: October 18, 2019 (version 2)

Copyright

© 2019, Yu et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 5,614
    views
  • 879
    downloads
  • 50
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Xiaodi Yu
  2. Olga Plotnikova
  3. Paul D Bonin
  4. Timothy A Subashi
  5. Thomas J McLellan
  6. Darren Dumlao
  7. Ye Che
  8. Yin Yao Dong
  9. Elisabeth P Carpenter
  10. Graham M West
  11. Xiayang Qiu
  12. Jeffrey S Culp
  13. Seungil Han
(2019)
Cryo-EM structures of the human glutamine transporter SLC1A5 (ASCT2) in the outward-facing conformation
eLife 8:e48120.
https://doi.org/10.7554/eLife.48120

Share this article

https://doi.org/10.7554/eLife.48120

Further reading

    1. Microbiology and Infectious Disease
    2. Structural Biology and Molecular Biophysics
    Ai Nguyen, Huaying Zhao ... Peter Schuck
    Research Article

    Genetic diversity is a hallmark of RNA viruses and the basis for their evolutionary success. Taking advantage of the uniquely large genomic database of SARS-CoV-2, we examine the impact of mutations across the spectrum of viable amino acid sequences on the biophysical phenotypes of the highly expressed and multifunctional nucleocapsid protein. We find variation in the physicochemical parameters of its extended intrinsically disordered regions (IDRs) sufficient to allow local plasticity, but also observe functional constraints that similarly occur in related coronaviruses. In biophysical experiments with several N-protein species carrying mutations associated with major variants, we find that point mutations in the IDRs can have nonlocal impact and modulate thermodynamic stability, secondary structure, protein oligomeric state, particle formation, and liquid-liquid phase separation. In the Omicron variant, distant mutations in different IDRs have compensatory effects in shifting a delicate balance of interactions controlling protein assembly properties, and include the creation of a new protein-protein interaction interface in the N-terminal IDR through the defining P13L mutation. A picture emerges where genetic diversity is accompanied by significant variation in biophysical characteristics of functional N-protein species, in particular in the IDRs.

    1. Microbiology and Infectious Disease
    2. Structural Biology and Molecular Biophysics
    Thomas Kuhlman
    Insight

    A new study reveals how naturally occurring mutations affect the biophysical properties of nucleocapsid proteins in SARS-CoV-2.